BioCryst Pharmaceuticals to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals to Present at Upcoming Investor Conferences

November 21, 2023 | Last Trade: US$8.75 0.13 -1.46

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6^th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th in Miami at 9:35 a.m. ET and the 35^th Annual Piper Sandler Healthcare Conference on Wednesday, November 29th in New York at 12:30 p.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Contact:
John Bluth
+1 919 859 7910
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$8.75
Daily Change:	-0.13 -1.46
Daily Volume:	124,289
Market Cap:	US$1.830B

July 09, 2025 BioCryst Pharmaceuticals to Highlight Patient-focused Research at the 2025 US HAEA National Summit June 27, 2025 BioCryst Pharmaceuticals Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million June 16, 2025 BioCryst Pharmaceuticals Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI June 13, 2025 BioCryst Pharmaceuticals: ORLADEYO® (berotralstat) Approved in Colombia June 06, 2025 BioCryst Pharmaceuticals Achieves Reimbursement for ORLADEYO Across all Major European Countries LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE